Spyre Therapeutics jumps on Q1 update, cash runway to H2 2029 and Phase 2 milestones
SYRE•Spyre Therapeutics shares are up after the company reported first-quarter 2026 results and reiterated it remains on track for six Phase 2 readouts in 2026. The update highlighted prior positive SPY001 Phase 2 induction data in ulcerative colitis and disclosed pro forma cash of about $1.18 billion with runway into the second half of 2029.
1) What’s moving SYRE today
Spyre Therapeutics (SYRE) is trading higher after releasing first-quarter 2026 financial results and a corporate update on May 5, 2026. The company paired the quarter’s financials with program milestones, including maintained expectations for multiple 2026 Phase 2 data readouts—keeping near- and mid-term catalysts in focus for biotech momentum traders. (stocktitan.net)
